Cell-Free Platform Will Unlock Broad Personalized Oncology Opportunities
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
11 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$7.00
87.7% undervalued intrinsic discount21 Aug
US$0.86
1Y
-82.9%7D
-2.3%